Estrogen in its various forms has long been used as a primary and secondary means of managing prostate cancer. Primarily it can be used in place of an LHRH ADT drug. In its secondary capacity, it can be employed in addition to an LHRH drug to help men cope with side effects arising from lack of...
Transdermal estradiol for androgen suppression in locally advanced prostate cancer
Duncan Gilbert, MA, MRCP, FRCR, PhD, University College London, London, UK, discusses the Phase III PATCH trial (ISRCTN70406718), which investigated transdermal estradiol as an alternative to traditional...
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.